•  
  •  
  •  
  •  

2022-08-08 16:14:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Sun Pharma Advanced Research Company Ltd Q1FY23 loss widens to Rs. 82.35 crores
  • Birla Precision Technologies Ltd Q1 FY2022-23 consolidated PAT declines QOQ to Rs. 6.08 crores
  • Sri Nachammai Cotton Mills Ltd Q1 FY23 net profit slips QoQ to Rs. 1.48 crore
  • Summit Securities Ltd consolidated Q1FY23 PAT surges to Rs. 11.93 crores
  • Astra Zeneca Pharma India Ltd Q1FY23 profit drops QoQ to Rs. 20.15 crores

Keywords Selected:  SUNPHARMA

Stock Report

  • Sun Pharma Advanced Research Company Ltd Q1FY23 loss widens to Rs. 82.35 crores
  • Sun Pharma Chairman, Israel Makov to retire on completion of term
  • Sun Pharmaceutical Industries Ltd Q1 FY2023 consolidated PAT rises to Rs. 2060.88 crores
  • Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI®
  • Sun Pharma Acquires Uractiv™ Portfolio from Fiterman Pharma in Romania
  • Sun Pharma to launch Brillo®, a first-in-class oral lipid-lowering drug in India
  • Sun Pharma Advanced Research Company Ltd Q4FY22 net loss widens to Rs. 71.05 crores
  • Sun Pharma announces US FDA Approval for Generic Mesalamine Extended Release Capsules
  • Sun Pharmaceutical Industries gets 10 observations from US FDA for Halol facility
  • Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
  • Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting
  • Sun Pharma to acquire Daiichi Sankyo's 11.28% stake in Zenotech Laboratories Ltd
  • Taro to acquire Alchemee from Galderma
  • Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crores
  • Sun Pharmaceutical Industries Ltd declares interim dividend of Rs. 7
  • Sun Pharma Q3FY22 consolidated profit up at Rs. 2058.8 crores
  • Sun Pharma launches solution for dry eye treatment with NCELL™ technology in Canada
  • Sun Pharma receives DCGI approval for Molxvir® in India
  • Sun Pharma announces US FDA Approval for Generic Amphotericin B Liposome Injection
  • SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting
  • SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma
  • SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
  • Sun Pharma arm DUSA to get $22.5 mn from Biofrontera for settlement of litigation
  • Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir® in India

Latest Post

  • Sun Pharma Advanced Research Company Ltd Q1FY23 loss widens to Rs. 82.35 crores
  • Birla Precision Technologies Ltd Q1 FY2022-23 consolidated PAT declines QOQ to Rs. 6.08 crores
  • Sri Nachammai Cotton Mills Ltd Q1 FY23 net profit slips QoQ to Rs. 1.48 crore
  • Summit Securities Ltd consolidated Q1FY23 PAT surges to Rs. 11.93 crores
  • Astra Zeneca Pharma India Ltd Q1FY23 profit drops QoQ to Rs. 20.15 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2021